OOIR: Observatory of International Research

Papers

(The TQCC of Journal of Nuclear Medicine is 10. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-02-01 to 2025-02-01.)

Article	Citations
Effect of COVID-19 Lockdown on Oncologic Patients Undergoing Treatment at a Tertiary-Care Hospital in India	178
Prostate-Specific Membrane Antigen Expression on PET/CT in Patients with Metastatic Castration-Resistant Prostate Cancer: A Retrospective Observational Study	161
Practicing Medicine in Wartime Ukraine	148
Noninvasive Assessment of Acute Graft-Versus-Host Disease of the Gastrointestinal Tract After Allogeneic Hemopoietic Stem Cell Transplantation Using¹⁸F-FDG PET	129
Feasibility of In Vivo Imaging of Fibroblast Activation Protein in Human Arterial Walls	113
Staging Liver Fibrosis by Fibroblast Activation Protein Inhibitor PET in a Human-Sized Swine Model	100
Validation of¹⁸F-rhPSMA-7 and¹⁸F-rhPSMA-7.3 PET Imaging Results with Histopathology from Salvage Surgery in Patients with Biochemical Recurrence of Prostate Cancer	97
Development of Fluorinated NP-59: A Revival of Cholesterol Use Imaging with PET	93
Distinction of Lymphoma from Sarcoidosis on¹⁸F-FDG PET/CT: Evaluation of Radiomics-Feature–Guided Machine Learning Versus Human Reader Performance	88
Combined PARP1-Targeted Nuclear Contrast and Reflectance Contrast Enhance Confocal Microscopic Detection of Basal Cell Carcinoma	85
Dynamic Tumor-Specific MHC-II Immuno-PET Predicts Checkpoint Inhibitor Immunotherapy Efficacy in Melanoma	84
Image-Guided High-Intensity Focused Ultrasound, A Novel Application for Interventional Nuclear Medicine?	83
Composite Prediction Score to Interpret Bone Focal Uptake in Hormone-Sensitive Prostate Cancer Patients Imaged with [¹⁸F]PSMA-1007 PET/CT	80
Albumin-Binding and Conventional PSMA Ligands in Combination with¹⁶¹Tb: Biodistribution, Dosimetry, and Preclinical Therapy	78
Imaging Neuroinflammation in Neurodegenerative Disorders	75
Stacking Ensemble Learning–Based [¹⁸F]FDG PET Radiomics for Outcome Prediction in Diffuse Large B-Cell Lymphoma	74
Letter to the Editor: “¹⁸F-FDOPA PET for the Noninvasive Prediction of Glioma Molecular Parameters: A Radiomics Study” [J Nucl Med 2022; 63:147–157]	74
Challenges and Promise for Nuclear Medicine in Africa	74
Perspectives on Theranostics and Nuclear Medicine	73
Myocardial External Efficiency in Asymptomatic Severe Primary Mitral Regurgitation Using¹¹C-Acetate PET	71
PET-Based Staging Is Cost-Effective in Early-Stage Follicular Lymphoma	65
18F-FDG PET/CT Imaging Biomarkers for Early and Late Evaluation of Response to First-Line Chemotherapy in Patients with Pancreatic Ductal Adenocarcinoma	61
¹¹C-PiB and¹²⁴I-Antibody PET Provide Differing Estimates of Brain Amyloid-β After Therapeutic Intervention	56
A Model System to Explore the Detection Limits of Antibody-Based Immuno-SPECT Imaging of Exclusively Intranuclear Epitopes	53
Deep Learning–Enabled Quantification of^99mTc-Pyrophosphate SPECT/CT for Cardiac Amyloidosis	52

Explainable Deep Learning Improves Physician Interpretation of Myocardial Perfusion Imaging	52
Reply: What Does an Imaging “Selection” Claim Actually Mean?	51
Advancing Clinical Trial Innovation in Pancreatic Cancer	51
Longitudinal Tau PET Using¹⁸F-Flortaucipir: The Effect of Relative Cerebral Blood Flow on Quantitative and Semiquantitative Parameters	50
A Prostate-Specific Membrane Antigen PET-Based Approach for Improved Diagnosis of Prostate Cancer in Gleason Grade Group 1: A Multicenter Retrospective Study	50
Adding Nontumor Radiomic Features to the Prognostic Model Is Bothersome but Useful	49
Receptor-Targeted Peptide Conjugates Based on Diphosphines Enable Preparation of^99mTc and¹⁸⁸Re Theranostic Agents for Prostate Cancer	48
¹⁷⁷Lu-PSMA (R)Evolution in Cancer Care: Is It Really Happening?	47
⁶⁸Ga-PSMA PET/CT–Based Atlas for Prostate Bed Recurrence After Radical Prostatectomy: Clinical Implications for Salvage Radiation Therapy Contouring Guidelines	47
Diagnostic Accuracy of MR Spectroscopic Imaging and¹⁸F-FET PET for Identifying Glioma: A Biopsy-Controlled Hybrid PET/MRI Study	47
Cyclooxygenases as Potential PET Imaging Biomarkers to Explore Neuroinflammation in Dementia	47
Advancing Nuclear Medicine in Australia over 3 Decades	46
A Life in Nuclear Medicine in Israel	46
Elevated Body Mass Index Is Associated with Improved Overall Survival in Castration-Resistant Prostate Cancer Patients Undergoing Prostate-Specific Membrane Antigen–Directed Radioligand Therapy	45
Biokinetics and Dosimetry of [¹⁷⁷Lu]Lu-Pentixather	45
Automated Motion Correction for Myocardial Blood Flow Measurements and Diagnostic Performance of⁸²Rb PET Myocardial Perfusion Imaging	44
A Life Study in Academic Leadership	44
Hemodynamic Insights into Combined Fractional Flow Reserve and Instantaneous Wave-Free Ratio Assessment Through Quantitative [¹⁵O]H₂O PET Myocardial Perfusion Imaging	43
Determining Hemodynamically Significant Coronary Artery Disease: Patient-Specific Cutoffs in Quantitative Myocardial Blood Flow Using [¹⁵O]H₂O PET Imaging	43
Update on the Evaluation of Thyroid Nodules	43
A Phase II, Open-Label Study to Assess Safety and Management Change Using ⁶⁸Ga-THP PSMA PET/CT in Patients with High-Risk Primary Prostate Cancer or Biochemical Recurrence After Radical Tre	43
V/Q SPECT/CT in the Time of COVID-19: Changing the Order to Improve Safety Without Sacrificing Accuracy	42
Dynamic Human Brain Imaging with a Portable PET Camera: Comparison to a Standard Scanner	41
MRI-Guided Motion-Corrected PET Image Reconstruction for Cardiac PET/MRI	41
Unraveling the Hypocalcemic Response to¹⁷⁷Lu-Prostate-Specific Membrane Antigen Therapy	41
Radionuclide Evaluation of Brain Death in the Post-McMath Era: Epilogue and Enigmata	39
Sex Differences and Caffeine Impact in Adenosine-Induced Hyperemia	39
A Deep-Learning–Based Partial-Volume Correction Method for Quantitative¹⁷⁷Lu SPECT/CT Imaging	39
Fibroblast-Activation Protein PET and Histopathology in a Single-Center Database of 324 Patients and 21 Tumor Entities	39
The Latest Advances in Imaging Crosstalk Between the Immune System and Fibrosis in Cardiovascular Disease	38
Detecting Metastatic Patterns of Oligometastatic Breast Cancer: A Comparative Analysis of¹⁸F-FDG PET/CT and Conventional CT Imaging	38
Governments Are Constitutionally Permitted to Provide “Vaccine Passports”—Some May Also Be Constitutionally Obligated to Do So	38
Precision of Myocardial Blood Flow and Flow Reserve Measurement During CZT SPECT Perfusion Imaging Processing: Intra- and Interobserver Variability	38
[¹⁸F]FDG and [⁶⁸Ga]Ga-FAPI-04–Directed Imaging for Outcome Prediction in Patients with High-Grade Neuroendocrine Neoplasms	37
Distinguishing Primary Lateral Sclerosis from Parkinsonian Syndromes with the Help of Advanced Imaging	37
Dosimetric Variability Across a Library of Computational Tumor Phantoms	36
Pioneering Research on Cancer Quality of Life and Outcomes	36
Study of ⁸⁹Zr-Pembrolizumab PET/CT in Patients With Advanced-Stage Non–Small Cell Lung Cancer	35
Interrogating Glioma-Associated Microglia and Macrophage Dynamics Under CSF-1R Therapy with Multitracer In Vivo PET/MRI	35
Translational PET Imaging of Nectin-4 Expression in Multiple Different Cancers with⁶⁸Ga-N188	34
Oncologic Staging with⁶⁸Ga-FAPI PET/CT Demonstrates a Lower Rate of Nonspecific Lymph Node Findings Than¹⁸F-FDG PET/CT	34
A Pilot Study of⁶⁸Ga-PSMA11 and⁶⁸Ga-RM2 PET/MRI for Biopsy Guidance in Patients with Suspected Prostate Cancer	34
Evaluation of Hepatotoxicity from Peptide Receptor Radionuclide Therapy in Patients with Gastroenteropancreatic Neuroendocrine Tumors and a Very High Liver Tumor Burden	33
Administration Routes for SSTR-/PSMA- and FAP-Directed Theranostic Radioligands in Mice	33
Looking at the Future of Prostate Cancer Treatment	33
Influence of Fc Modifications and IgG Subclass on Biodistribution of Humanized Antibodies Targeting L1CAM	32
Reimbursement Approaches for Radiopharmaceutical Dosimetry: Current Status and Future Opportunities	32
Debating the Future of Nuclear Medicine: The Greek Experience	31
Impact of⁶⁸Ga-FAPI PET/CT on Staging and Oncologic Management in a Cohort of 226 Patients with Various Cancers	31
c-MET Receptor–Targeted Fluorescence on the Road to Image-Guided Surgery in Penile Squamous Cell Carcinoma Patients	31

The Future of Nuclear Medicine in the United States	31
Preclinical Comparison of the⁶⁴Cu- and⁶⁸Ga-Labeled GRPR-Targeted Compounds RM2 and AMTG, as Well as First-in-Humans [⁶⁸Ga]Ga-AMTG PET/CT	31
Impact of Single-Time-Point Estimates of¹⁷⁷Lu-PRRT Absorbed Doses on Patient Management: Validation of a Trained Multiple-Linear-Regression Model in 159 Patients and 477 Therapy Cycles	30
Redesigned Curricula, Stringent Licensing Criteria, and Integrated Independence Are Conditions for a Bright Future for Nuclear Medicine in the United States	30
⁶⁸Ga-DOTATATE Prepared from Cyclotron-Produced⁶⁸Ga: An Integrated Solution from Cyclotron Vault to Safety Assessment and Diagnostic Efficacy in Neuroendocrine Cancer Patients	29
Accuracy of ¹⁸F-Fluorocholine PET for the Detection of Parathyroid Adenomas: Prospective Single-Center Study	28
Long Versus Short Axial Field of View Immuno-PET/CT: Semiquantitative Evaluation for⁸⁹Zr-Trastuzumab	28
Enhancing ²²³Ra Treatment Efficacy by Anti-β1 Integrin Targeting	28
¹⁶¹Tb-DOTATOC Production Using a Fully Automated Disposable Cassette System: A First Step Toward the Introduction of¹⁶¹Tb into the Clinic	28
In Vivo Visualization and Quantification of Neutrophil Elastase in Lungs of COVID-19 Patients: A First-in-Humans PET Study with¹¹C-NES	28
Incidental Airway Findings on PET/CT with¹⁸F-PSMA	27
MIRD Pamphlet No. 28, Part 2: Comparative Evaluation of MIRDcalc Dosimetry Software Across a Compendium of Diagnostic Radiopharmaceuticals	27
Tumor Location Relative to the Spleen Is a Prognostic Factor in Lymphoma Patients: A Demonstration from the REMARC Trial	27
Effectiveness of²²⁵Ac-Labeled Anti-EGFR Radioimmunoconjugate in EGFR-Positive Kirsten Rat Sarcoma Viral Oncogene and BRAF Mutant Colorectal Cancer Models	27
Molecular Imaging of Systemic and Cardiac Amyloidosis: Recent Advances and Focus on the Future	26
Using Molecular Imaging to Enhance Decision Making in the Management of Pituitary Adenomas	26
Clinical Experience with [²²⁵Ac]Ac-PSMA Treatment in Patients with [¹⁷⁷Lu]Lu-PSMA–Refractory Metastatic Castration-Resistant Prostate Cancer	26
Molecular Signature of ¹⁸F-FDG PET Biomarkers in Newly Diagnosed Multiple Myeloma Patients: A Genome-Wide Transcriptome Analysis from the CASSIOPET Study	26
The PRIMARY Score: Using intra-prostatic PSMA PET/CT patterns to optimise prostate cancer diagnosis.	26
Radioiodine Ablation of Thyroid Remnants in Patients with Graves’ Orbitopathy	25
Role of¹⁸F-FDG PET/CT in Large Vessel Vasculitis and Polymyalgia Rheumatica	25
Head-to-Head Comparison of ⁶⁸Ga-NOTA (⁶⁸Ga-NGUL) and ⁶⁸Ga-PSMA-11 in Patients with Metastatic Prostate Cancer: A Prospective Study	25
A Multicenter Study on Observed Discrepancies Between Vendor-Stated and PET-Measured⁹⁰Y Activities for Both Glass and Resin Microsphere Devices	25
Diagnostic Contribution of Contrast-Enhanced CT as Compared with Unenhanced Low-Dose CT in PET/CT Staging and Treatment Response Assessment of¹⁸F-FDG–Avid Lymphomas: A Prospective Study	25
Primary Hyperparathyroidism: Defining the Appropriate Preoperative Imaging Algorithm	25
The Potential Contribution of Radiopharmaceutical Therapies in Managing Oligometastatic Disease	24
Glucagon-like Peptide-1 Receptor as Emerging Target: Will It Make It to the Clinic?	24
Exploiting the MUC5AC Antigen for Noninvasive Identification of Pancreatic Cancer	24
Is ¹⁸F-FDG PET/CT Effective in Identifying True Residual Disease After Treatment of Pediatric PTLD?	24
An¹⁸F-FDG PET/CT and Mean Lung Dose Model to Predict Early Radiation Pneumonitis in Stage III Non–Small Cell Lung Cancer Patients Treated with Chemoradiation and Immunotherapy	24
Safety and Efficacy ofPara-Aminohippurate Coinfusion for Renal Protection During Peptide Receptor Radiotherapy in Patients with Neuroendocrine Tumors	24
⁶⁸Ga-FAP-2286 PET of Solid Tumors: Biodistribution, Dosimetry, and Comparison with¹⁸F-FDG	23
Diagnostic Accuracy of⁶⁸Ga-FAPI Versus¹⁸F-FDG PET in Patients with Various Malignancies	23
Interrogating the Theranostic Capacity of a MUC16-Targeted Antibody for Ovarian Cancer	23
[¹⁷⁷Lu]Lu-PSMA Therapy as an Individual Treatment Approach for Patients with High-Grade Glioma: Dosimetry Results and Critical Statement	23
Impact of ¹⁸F-FET PET/MRI on Clinical Management of Brain Tumor Patients	23
Simultaneous Mapping of Vasculature, Hypoxia, and Proliferation Using Dynamic Susceptibility Contrast MRI, ¹⁸F-FMISO PET, and ¹⁸F-FLT PET in Relation to Contrast Enhancement in N	23
Could FAP-Targeted Molecular Imaging Replace¹⁸F-FDG for Standard-of-Care Oncologic PET?	22
Superior Tumor Detection for⁶⁸Ga-FAPI-46 Versus¹⁸F-FDG PET/CT and Conventional CT in Patients with Cholangiocarcinoma	22
Radiolabeled Somatostatin Receptor Antagonist Versus Agonist for Peptide Receptor Radionuclide Therapy in Patients with Therapy-Resistant Meningioma: PROMENADE Phase 0 Study	22
In Vivo Cerebral Imaging of Mutant Huntingtin Aggregates Using¹¹C-CHDI-180R PET in a Nonhuman Primate Model of Huntington Disease	22
Cerenkov Luminescence Imaging in Prostate Cancer: Not the Only Light That Shines	22
Initial Results of⁶⁸Ga-FAPI-46 PET/MRI to Assess Response to Neoadjuvant Chemotherapy in Breast Cancer	22
Infection Imaging: Focus on New Tracers?	22
Synthesis of⁶⁴Cu-,⁵⁵Co-, and⁶⁸Ga-Labeled Radiopharmaceuticals Targeting Neurotensin Receptor-1 for Theranostics: Adjusting In Vivo Distribution Using Multiamine Macroc	22
Response to Combined Peptide Receptor Radionuclide Therapy and Checkpoint Immunotherapy with Ipilimumab Plus Nivolumab in Metastatic Merkel Cell Carcinoma	22
Detection of IL12/23p40 via PET Visualizes Inflammatory Bowel Disease	22
Whole-Body PET Imaging: A Catalyst for Whole-Person Research?	22
State of the Art: Precision Surgery Guided by Intraoperative Molecular Imaging	22
Hot Spot Imaging in Cardiovascular Diseases: An Information Statement from SNMMI, ASNC, and EANM	22
Dose–Response Relationship in Patients with Liver Metastases from Neuroendocrine Neoplasms Undergoing Radioembolization with⁹⁰Y Glass Microspheres	21
Summary: Appropriate Use Criteria for Estrogen Receptor–Targeted PET Imaging with 16α-¹⁸F-Fluoro-17β-Fluoroestradiol	21
Fast and Accurate Amyloid Brain PET Quantification Without MRI Using Deep Neural Networks	21
Alzheimer Disease: Standard of Diagnosis, Treatment, Care, and Prevention	21
Prostate-Specific Membrane Antigen–Targeted Imaging and Its Correlation with HOXB13 Expression	21
Prospective, Single-Arm Trial Evaluating Changes in Uptake Patterns on Prostate-Specific Membrane Antigen–Targeted ¹⁸F-DCFPyL PET/CT in Patients with Castration-Resistant Prostate Cancer St	21
Theranostics in Hematooncology	21
Ambient Light Resistant Shortwave Infrared Fluorescence Imaging for Preclinical Tumor Delineation via the pH Low-Insertion Peptide Conjugated to Indocyanine Green	21
SNMMI Consensus Statement on Patient Selection and Appropriate Use of¹⁷⁷Lu-PSMA-617 Radionuclide Therapy	21
The Role of Fibroblast Activation Protein in Glioblastoma and Gliosarcoma: A Comparison of Tissue,⁶⁸Ga-FAPI-46 PET Data, and Survival Data	21
Validation of the ΔSUV_maxfor Interim PET Interpretation in Diffuse Large B-Cell Lymphoma on the Basis of the GAINED Clinical Trial	21
Improved Primary Staging of Marginal-Zone Lymphoma by Addition of CXCR4-Directed PET/CT	21
Do Bone Scans Overstage Disease Compared with PSMA PET at Initial Staging? An International Multicenter Retrospective Study with Masked Independent Readers	21
Application of the Lugano Classification for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The PRoLoG Consensus Initiative (Part 2—Technical)	21
An Intrapatient Dosimetry Comparison of¹⁷⁷Lu-rhPSMA-10.1 and¹⁷⁷Lu-PSMA-I&T in Patients with Metastatic Castration-Resistant Prostate Cancer	20
Direct Attenuation Correction Using Deep Learning for Cardiac SPECT: A Feasibility Study	20
Development and Preclinical Evaluation of [²¹¹At]PSAt-3-Ga: An Inhibitor for Targeted α-Therapy of Prostate Cancer	20
Quality Assurance Considerations in Radiopharmaceutical Therapy Dosimetry Using PLANETDose: An International Atomic Energy Agency Study	20
In Vivo ¹⁸F-Flortaucipir PET Does Not Accurately Support the Staging of Progressive Supranuclear Palsy	20
Investigating Tau and Amyloid Tracer Skull Binding in Studies of Alzheimer Disease	20
First-in-Human Total-Body PET/CT Imaging Using⁸⁹Zr-Labeled MUC5AC Antibody in a Patient with Pancreatic Adenocarcinoma	20
Predicting Outcomes of Indeterminate Bone Lesions on¹⁸F-DCFPyL PSMA PET/CT Scans in the Setting of High-Risk Primary or Recurrent Prostate Cancer	20
Toward a Universal Readout for¹⁸F-Labeled Amyloid Tracers: The CAPTAINs Study	20
Clinical Translation of Targeted α-Therapy: An Evolution or a Revolution?	20
Biodistribution, Dosimetry, and Pharmacokinetics of⁶⁸Ga-CBP8: A Type I Collagen–Targeted PET Probe	20
Granzyme B PET/CT Imaging Evaluates Early Response to Immunotherapy in Gastric Cancer	19
The Association of Age-Related and Off-Target Retention with Longitudinal Quantification of [¹⁸F]MK6240 Tau PET in Target Regions	19
One Bite from the Apple, One Bite from the Orange in the PRECISE-MDT Study	19
Optimized Whole-Body PET MRI Sequence Workflow in Pediatric Hodgkin Lymphoma Patients	19
Preclinical Evaluation of²²⁶Ac as a Theranostic Agent: Imaging, Dosimetry, and Therapy	19

Optimizing the Therapeutic Index of sdAb-Based Radiopharmaceuticals Using Pretargeting	19
α-Synuclein PET and Parkinson Disease Therapeutic Trials: Ever the Twain Shall Meet?	19
Validation of an Artificial Intelligence–Based Prediction Model Using 5 External PET/CT Datasets of Diffuse Large B-Cell Lymphoma	19
Utility of ²¹¹At-Trastuzumab for the Treatment of Metastatic Gastric Cancer in the Liver: Evaluation of a Preclinical α-Radioimmunotherapy Approach in a Clinically Relevant Mouse Model	19
Association Between CA 15-3 and¹⁸F-FDG PET/CT Findings in Recurrent Breast Cancer Patients at a Tertiary Referral Hospital in Kenya	19
Normal-Tissue Tolerance to Radiopharmaceutical Therapies, the Knowns and the Unknowns	19
Nuclear Medicine and Artificial Intelligence: Best Practices for Evaluation (the RELAINCE Guidelines)	18
[¹⁸F]Fluorthanatrace PET in Ovarian Cancer: Comparison with [¹⁸F]FDG PET, Lesion Location, Tumor Grade, and Breast Cancer Gene Mutation Status	18
2024 SNMMI Highlights Lecture: General Clinical Specialties	18
Total-Body PET Multiparametric Imaging of Cancer Using a Voxelwise Strategy of Compartmental Modeling	18
Deep Semisupervised Transfer Learning for Fully Automated Whole-Body Tumor Quantification and Prognosis of Cancer on PET/CT	18
Quantitative Accuracy Assessment of the NeuroEXPLORER for Diverse Imaging Applications: Moving Beyond Standard Evaluations	18
Solving Challenging Puzzles	18
Beyond Average: α-Particle Distribution and Dose Heterogeneity in Bone Metastatic Prostate Cancer	18
Localized In Vivo Prodrug Activation Using Radionuclides	18
Comparability of Quantifying Relative Lung Ventilation with Inhaled^99mTc-Technegas and¹³³Xe in Patients Undergoing Evaluation for Lung Transplantation	18
Practical Guide for Interpreting and Reporting Cardiac PET Measurements of Myocardial Blood Flow: An Information Statement from the American Society of Nuclear Cardiology, and the Society of Nuclear M	18
Diagnostic Performance and Clinical Impact of ⁶⁸Ga-PSMA-11 PET/CT Imaging in Early Relapsed Prostate Cancer After Radical Therapy: A Prospective Multicenter Study (IAEA-PSMA Study)	17
Exploring Vessel Wall Biology In Vivo by Ultrasensitive Total-Body PET	17
Is Routine Dosimetry Really Happening?	17
Imaging Pituitary Vasopressin 1B Receptor in Humans with the PET Radiotracer ¹¹C-TASP699	17
Whole-Body PET Imaging in Humans Shows That¹¹C-PS13 Is Selective for Cyclooxygenase-1 and Can Measure the In Vivo Potency of Nonsteroidal Antiinflammatory Drugs	17
Single-Domain Antibody Theranostics on the Horizon	17
First-in-Humans Evaluation of ¹⁸F-SMBT-1, a Novel ¹⁸F-Labeled Monoamine Oxidase-B PET Tracer for Imaging Reactive Astrogliosis	17
⁶⁸Ga-PSMA PET/CT for Response Assessment and Outcome Prediction in Metastatic Prostate Cancer Patients Treated with Taxane-Based Chemotherapy	17
Imaging of the Aging Human Brain	17
⁶⁸Ga-FAPI as a Diagnostic Tool in Sarcoma: Data from the ⁶⁸Ga-FAPI PET Prospective Observational Trial	17
What Is Theranostics?	17
PET Imaging and Protein Expression of Prostate-Specific Membrane Antigen in Glioblastoma: A Multicenter Inventory Study	17
Analysis of Short-Term and Stable DNA Damage in Patients with Differentiated Thyroid Cancer Treated with ¹³¹I in Hypothyroidism or with Recombinant Human Thyroid-Stimulating Hormone for Rem	17
High Tumor Uptake on¹⁸F-FDOPA PET/CT Indicates Poor Prognosis in Patients with Metastatic Midgut Neuroendocrine Tumors: A Study from the Groupe d’étude des Tumeurs Endocrines and ENDOCAN-RE	17
Incidental Focal⁶⁸Ga-FAPI-46 Uptake in a Urachal Remnant: A Potential Pitfall Mimicking a Malignant Peritoneal Lesion	17
[¹⁸F]FDG PET/CT in the Initial Staging and Restaging of Soft-Tissue or Bone Sarcoma in Patients with Negative or Equivocal Findings for Metastases or Limited Recurrence on Conventional Work	17
First-in-Human Safety, Imaging, and Dosimetry of a Carbonic Anhydrase IX–Targeting Peptide, [⁶⁸Ga]Ga-DPI-4452, in Patients with Clear Cell Renal Cell Carcinoma	17
Diverse Imaging Methods May Influence Long-Term Oncologic Outcomes in Oligorecurrent Prostate Cancer Patients Treated with Metastasis-Directed Therapy (the PRECISE-MDT Study)	16
PET/CT with Myocardial Blood Flow Assessment Is Prognostic of Cardiac Allograft Vasculopathy Progression and Clinical Outcomes	16
From Scientist to Analyst to Strategist	16
Adverse Clinical Events at the Injection Site Are Exceedingly Rare After Reported Radiopharmaceutical Extravasation in Patients Undergoing^99mTc-MDP Whole-Body Bone Scintigraphy: A 12-Year E	16
Absorbed Dose–Response Relationship in Patients with Gastroenteropancreatic Neuroendocrine Tumors Treated with [¹⁷⁷Lu]Lu-DOTATATE: One Step Closer to Personalized Medicine	16
Harnessing α-Emitting Radionuclides for Therapy: Radiolabeling Method Review	16
Imaging Demyelinated Axons After Spinal Cord Injuries with PET Tracer [¹⁸F]3F4AP	16
Repetitive Early⁶⁸Ga-FAPI PET Acquisition Comparing⁶⁸Ga-FAPI-02,⁶⁸Ga-FAPI-46, and⁶⁸Ga-FAPI-74: Methodologic and Diagnostic Implications for Malignant, Infla	16
Imaging Androgen Receptors in Breast Cancer with ¹⁸F-Fluoro-5α-Dihydrotestosterone PET: A Pilot Study	16
Lesion Dosimetry for [¹⁷⁷Lu]Lu-PSMA-617 Radiopharmaceutical Therapy Combined with Stereotactic Body Radiotherapy in Patients with Oligometastatic Castration-Sensitive Prostate Cancer	16
Total-Body PET System Designs with Axial and Transverse Gaps: A Study of Lesion Quantification and Detectability	16
Prostate Cancer Treatment:¹⁷⁷Lu-PSMA-617 Considerations, Concepts, and Limitations	16
Reply: On Facilitating the End of the Linear No-Threshold Era	16
Borderline Findings inO-(2-[¹⁸F]-Fluoroethyl)-l-Tyrosine PET of Patients with Suspected Glioma Relapse: Role in Clinical Practice	16
The Influence of Specific Activity on the Biodistribution of ¹⁸F-rhPSMA-7.3: A Retrospective Analysis of Clinical Positron Emission Tomography Data	15
Dual PET Imaging in Bronchial Neuroendocrine Neoplasms: The NETPET Score as a Prognostic Biomarker	15
¹⁷⁷Lu-PSMA617 and the VISION Trial: One of the Greatest Success Stories in the History of Nuclear Medicine	15
Radioembolization Versus Bland or Chemoembolization for Liver-Dominant Neuroendocrine Tumors: Is It an Either/Or Question?	15
An Analysis of the Distribution of PSMA PET/CT–Positive Lymph Nodes and Their Coverage by Different Elective Nodal Radiation Volumes in Postoperative Prostate Cancer Patients	15
PSMA- and GRPR-Targeted PET: Results from 50 Patients with Biochemically Recurrent Prostate Cancer	15
Mapping Arginase Expression with ¹⁸F-Fluorinated Late-Generation Arginase Inhibitors Derived from Quaternary α-Amino Acids	15
PSMA PET/CT and Therapy Response Evaluation in Metastatic Prostate Cancer: Is It Time to Surpass the Old Way?	15
Left Ventricular Strain from Myocardial Perfusion PET Imaging: Method Development and Comparison to 2-Dimensional Echocardiography	15
PSMA Is Not Specific to Prostate Cancer	15
Hybrid¹⁸F-Fluoroethyltyrosine PET and MRI with Perfusion to Distinguish Disease Progression from Treatment-Related Change in Malignant Brain Tumors: The Quest to Beat the Toughest Cases	15
Molecular Imaging of Neuroendocrine Prostate Cancer by Targeting Delta-Like Ligand 3	15
Defining Myeloma and Advancing Treatment Options	15
Is¹⁸F-FDG Metabolic Tumor Volume in Lymphoma Really Happening?	15
RESIST-PC: U.S. Academic Foray into PSMA Theranostic Trials	15
Molecular Imaging Leadership in Academia and Industry	15
Antibody Engineering for Nuclear Imaging and Radioimmunotherapy	15
PD-L1 PET/CT imaging with radiolabeled durvalumab in patients with advanced stage non-small cell lung cancer.	15
2022 SNMMI Highlights Lecture: Oncology and Therapy, Part 2	14
Fibroblast Activation Protein and Glycolysis in Lymphoma Diagnosis: Comparison of⁶⁸Ga-FAPI PET/CT and¹⁸F-FDG PET/CT	14
Correlation of ⁶⁸Ga-FAPi-46 PET Biodistribution with FAP Expression by Immunohistochemistry in Patients with Solid Cancers: Interim Analysis of a Prospective Translational Exploratory Study	14
Theragnostics: A Neologism That Generates Schism—The Hellenic Thesis	14
Theranostics for Meningioma on the Rise: New EANM/EANO/RANO/SNMMI Guidelines Pave the Way to Improved Patient Outcomes Using Radiolabeled Somatostatin Receptor Ligands	14
Pattern of Failure in Patients with Biochemical Recurrence After PSMA Radioguided Surgery	14
PSMA Theranostics: Is the Time Ripe to Pave the Way to Further Tumor Entities?	14
Immuno-PET/CT Imaging of Trop2 with [¹⁸F]AlF-RESCA-T4 Differentiates Lung Cancer from Inflammation	14
Prognostic Value of Bone Marrow Metabolism on Pretreatment ¹⁸F-FDG PET/CT in Patients with Metastatic Melanoma Treated with Anti-PD-1 Therapy	14
Fibroblast Activation Protein Inhibitor Tracers and Their Preclinical, Translational, and Clinical Status in China	14
The Impact of Baseline PSMA PET/CT Versus CT on Outcomes of²²³Ra Therapy in Metastatic Castration-Resistant Prostate Cancer Patients	14
Reply LTE, Single time point tumour dosimetry assuming normal distribution of tumour kinetics	14
Extravasation of Diagnostic Radiopharmaceuticals: A Wolf in Sheep’s Clothing?	14
Real-World Comparison of Cabazitaxel Versus¹⁷⁷Lu-PSMA Radiopharmaceutical Therapy in Metastatic Castration-Resistant Prostate Cancer	14
Addition of Peptide Receptor Radiotherapy to Immune Checkpoint Inhibition Therapy Improves Outcomes in Neuroendocrine Tumors	14
Liver enzyme elevation after ¹⁷⁷Lu-PSMA radioligand therapy for metastasized castration-resistant prostate cancer	14
Nuclear Medicine: The Essentials	14
[¹⁸F]FET PET/MRI: An Accurate Technique for Detection of Small Functional Pituitary Tumors	14
HER2-Low Breast Cancer Can Be Visualized by HER2 PET	14
Experience with a Perfusion-Only Screening Protocol for Evaluation of Pulmonary Embolism During the COVID-19 Pandemic Surge	14
The importance of an adequate surgical template during salvage lymph node dissection for node-recurrent prostate cancer	14
Whole-Body Parametric Imaging of ¹⁸F-FDG PET Using uEXPLORER with Reduced Scanning Time	14
Targeting Fibroblast Activation Protein for Molecular Imaging of Fibrotic Remodeling in Pulmonary Arterial Hypertension	14
Need for Objective Task-Based Evaluation of Image Segmentation Algorithms for Quantitative PET: A Study with ACRIN 6668/RTOG 0235 Multicenter Clinical Trial Data	14
Diagnostic Radiopharmaceuticals: A Sustainable Path to the Improvement of Patient Care	14
α-Synuclein Seeding Amplification Assay: A Breakthrough in Diagnosing Parkinson Disease?	13
Impact of the Reference Multiple-Time-Point Dosimetry Protocol on the Validity of Single-Time-Point Dosimetry for [¹⁷⁷Lu]Lu-PSMA-I&T Therapy	13
Lung Dose Measured on Postradioembolization ⁹⁰Y PET/CT and Incidence of Radiation Pneumonitis	13
Factors Associated with Myocardial Uptake on Oncologic Somatostatin PET Investigations and Differentiation from Myocardial Uptake of Acute Myocarditis	13